Fenofibrate: Difference between revisions
No edit summary |
Michal Harel (talk | contribs) No edit summary |
||
| (One intermediate revision by one other user not shown) | |||
| Line 1: | Line 1: | ||
<StructureSection load='' size='340' side='right' caption=' | <StructureSection load='' size='340' side='right' caption='Fenofibrate' scene='97/977745/Cv/1'> | ||
Fenofibrate (sold under the brand names Tricor, Fenobrat etc.), is an oral medication of the fibrate class used to treat abnormal blood lipid levels.<ref name="a2">"Fenofibric Acid/Fenofibrate Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 3 March 2019.</ref> It is less commonly used compared than statins because it treats a different type of cholesterol abnormality to statins. While statins have strong evidence for reducing heart disease and death, there is evidence to suggest that fenofibrate also reduces to the risk of heart disease and death. However, this seems only to apply to specific populations of people with elevated triglyceride levels and reduced high-density lipoprotein (HDL) cholesterol.<ref name="a2">"Fenofibric Acid/Fenofibrate Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 3 March 2019.</ref><ref name="a3">PMID:20228404</ref><ref name="a4">PMID:31562117</ref> See also [https://en.wikipedia.org/wiki/Fenofibrate]. | Fenofibrate (sold under the brand names Tricor, Fenobrat etc.), is an oral medication of the fibrate class used to treat abnormal blood lipid levels.<ref name="a2">"Fenofibric Acid/Fenofibrate Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 3 March 2019.</ref> It is less commonly used compared than statins because it treats a different type of cholesterol abnormality to statins. While statins have strong evidence for reducing heart disease and death, there is evidence to suggest that fenofibrate also reduces to the risk of heart disease and death. However, this seems only to apply to specific populations of people with elevated triglyceride levels and reduced high-density lipoprotein (HDL) cholesterol.<ref name="a2">"Fenofibric Acid/Fenofibrate Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 3 March 2019.</ref><ref name="a3">PMID:20228404</ref><ref name="a4">PMID:31562117</ref> See also [https://en.wikipedia.org/wiki/Fenofibrate]. | ||
| Line 10: | Line 10: | ||
<scene name='97/977745/Cv/2'>PPARalpha ligand binding domain-fenofibric acid co-crystals</scene> ([[6lx4]]). | <scene name='97/977745/Cv/2'>PPARalpha ligand binding domain-fenofibric acid co-crystals</scene> ([[6lx4]]). | ||
<scene name='97/977745/First_binding_site/1'>First fenofibric acid binding site</scene>. | <scene name='97/977745/First_binding_site/1'>First fenofibric acid binding site</scene>. Water molecules are shown as red spheres. | ||
</StructureSection> | </StructureSection> | ||
== References == | == References == | ||
<references/> | <references/> | ||